2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150Sermorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). GHRH is a naturally occurring peptide secreted by the hypothalamus to stimulate growth hormone (GH) production in the anterior pituitary gland.
Structurally, sermorelin is a 29–amino acid peptide fragment of GHRH that retains full biological activity in terms of binding to pituitary receptors and triggering GH release [1].
Originally, sermorelin was developed as a diagnostic tool to assess pituitary function. Over time, its use has expanded into research exploring potential roles as a secretagogue in endocrine regulation, metabolism, and aging biology.
Sermorelin stimulates the pituitary to produce and secrete GH, which in turn drives the liver and peripheral tissues to generate insulin-like growth factor-1 (IGF-1), the primary mediator of bone elongation and linear growth.
Clinical trials in children with impaired growth velocity have shown that sermorelin administration can increase growth rate and promote catch-up growth.
Specifically, once-daily subcutaneous Sermorelin (30 µg/kg body weight) at bedtime was effective in treatment of prepubertal children with idiopathic GH deficiency [2].
Although sermorelin-treated children demonstrated less height improvements compared to 30 µg/kg/day of somatropin (bioidentical GH), sermorelin was likely safer and better tolerated.
Unlike direct GH therapy, sermorelin does not appear to excessively elevate circulating GH or IGF-1 levels, potentially lowering the risk of disproportionate bone growth or metabolic complications.
In this context, sermorelin is best understood as a diagnostic and therapeutic tool that can support normal developmental trajectories in children with specific types of growth impairment.
However, long-term data remain limited, and not all forms of growth delay respond equally, underscoring the importance of careful patient selection in research and clinical settings.
Preclinical studies suggest that GHRH analogs similar to sermorelin can exert anti-proliferative effects in certain cancer models. Mechanistically, these peptides appear to influence signaling pathways that regulate apoptosis, angiogenesis, and cell cycle progression [3].
A transcriptomic screen for candidate compounds in treatment-resistant glioma patients identified sermorelin as a candidate compound effective against the glioma [4].
Among screened compounds, sermorelin emerged as the most promising agent for recurrent gliomas, especially those with high-grade tumors, IDH-wildtype status, and 1p/19q non-codeletion.
This study suggests that sermorelin may inhibit glioma cell proliferation by blocking the cell cycle, although clinical validation is required.
GH and IGF-1 support osteoblast activity, increase bone turnover, and may help reverse age‐related loss of bone mass. These hormones also support muscle growth and maintenance along with tissue repair [5, 6]. As a GH secretagogue, sermorelin may mitigate some aspects of age-related decline in bone health. However, specific trials of sermorelin in aging adults focused on bone density remain limited.
A single-blind, randomized, placebo-controlled trial of 19 people investigated the effects of nightly subcutaneous sermorelin at 10 µg/kg for 16 weeks. Results showed [7]:
While body weight, fat mass, and testosterone levels remained stable, these findings suggest sermorelin may mitigate age-related GH/IGF-1 decline and corresponding muscle mass loss.
In clinical and research use, sermorelin has generally been regarded as safe and well tolerated, especially in comparison to direct recombinant growth hormone therapy.
Because it acts as a secretagogue, stimulating the body’s own pulsatile growth hormone release rather than providing supraphysiologic doses, its endocrine profile is considered closer to natural physiology.
The most frequently reported adverse effects are mild and transient, such as injection site reactions, flushing sensation, and nausea.
Serious side effects are rare in published reports, and no consistent evidence suggests long-term harm at research dosages.
However, as with other growth hormone-modulating therapies, caution is advised in individuals with active malignancy, since GH and IGF-1 pathways can influence cell proliferation.
Overall, the safety data indicate a favorable risk profile for sermorelin within short- to medium-term use, though robust long-term clinical studies are limited.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Sermorelin is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
In the paper, sermorelin is written as GHRH(1-29)NH2, a GHRH analog that was sold under the brand Geref Diagnostic. The paper describes sermorelin (SERM) as a GH-releasing hormone analog and one of the GH secretagogues it investigated. A review names sermorelin as an example of a growth hormone-releasing hormone analogue among the agents most commonly encountered in clinical practice and online self-administration protocols.
Sermorelin is a growth hormone-releasing hormone analogue that is included in the prohibited list of the World Antidoping Agency. WADA regulations state that the use of growth hormone-releasing hormones, which includes sermorelin, is prohibited in sports. WADA also prohibits administration of growth hormone releasing hormone and its synthetic analogs.
In laboratory work on human urine samples, sermorelin was analysed by liquid chromatography coupled to high resolution mass spectrometry using a Quadrupole-Orbitrap instrument, after immunopurification with magnetic beads. A refined sample preparation approach was developed for the target peptides, including sermorelin, in urine, combining an initial ultrafiltration step followed by solid-phase extraction. A sensitive liquid chromatography-tandem mass spectrometry method was developed to detect GHRH analogs and their metabolites, including the sermorelin metabolite sermorelin(3-29)-NH2, in spiked urine.
In an in vitro study of urine, the method reached limits of detection for sermorelin between 5 and 25 pg/mL. The limits of identification were between 25 and 50 pg/mL, and these were established even without immuno-affinity purification steps. Other in vitro results report general limits for target peptides of 1 ng/ml or less, and for growth hormone-releasing hormone analogues a limit of detection of 0.2 ng/mL and a limit of identification of 0.5 ng/mL, but these are not specific to sermorelin.
In stability experiments on urine samples, sermorelin and its metabolite were found to degrade rapidly at temperatures above 4 °C and at pH values below 7. The study noted that proper handling of urine samples is important to avoid degradation of these peptide hormones, especially sermorelin and its metabolite. More generally, the analysis of GHRH and its analogs in urine was described as challenging because of their in vivo instability, rapid renal clearance, and low urinary concentrations.
The only sermorelin metabolite named in these laboratory studies is sermorelin(3-29)-NH2, which was used in in vitro work with spiked urine. In that study, sermorelin(3-29)-NH2 was used as a reference material, together with parent peptides, to develop a liquid chromatography-tandem mass spectrometry method for detecting GHRH administration. A separate in vitro study investigated the metabolism of sermorelin in fortified urine, alongside tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex. That in vitro work identified nineteen major metabolites across the GHRH analogs, which were synthesized and characterized, but the facts do not state which of them come from sermorelin.
In an observational study of human recurrent glioma patients, sermorelin was found to be suitable for those with high grade, IDH-wildtype and 1p/19q non-codeletion status. The Kaplan-Meier analysis in these patients showed that the benefit from sermorelin was independent of postoperative adjuvant treatment. The authors reported that recurrent glioma patients were sensitive to sermorelin, which was described as acting by inhibiting glioma cell proliferation and enhancing immune response.
In observational human data, GO and KEGG pathway analyses suggested that sermorelin may inhibit tumor cell proliferation by cell cycle blocking. The same observational human study also reported that sermorelin was related to the immune system process and negatively regulated immune checkpoints and M0 macrophages.
A review states that current clinical efficacy data on growth hormone secretagogues, which include sermorelin, are largely lacking. The same review describes growth hormone secretagogues as a potential adjunctive therapy for some symptoms of hypogonadism, but notes that their clinical efficacy data largely remain lacking.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.